|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 2 | Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial显示文摘 | Ronald P DeMatteo Karla V Ballman Cristina R Antonescu Robert G Maki Peter WT Pisters George D Demetri Martin E Blackstein Charles D Blanke Margaret von Mehren Murray F Brennan Shreyaskumar Patel Martin D McCarter Jonathan A Polikoff Benjamin R Tan Kouros | 2009 | The Lancet2009，，9669： | 2 |
| 3 | Holographic memories显示文摘 | Demetri P Fai M | 1995 | Scientific American1995，273，5： | 1 |
| 4 | Chronic liver al- lograft rejection: a National Institute of Diabetes and Digestive and Kidney Diseases interinstitutional study analyzing the relia- bility of current criteria and proposal of an expanded definition 显示文摘 | Demetris A J Seaberg E C Batts K P | 1998 | Am J SurgPathol1998，22，1： | 1 |
| 5 | Protein Struc- tures and Information Extraction from Biological Texts : The PASTA System 显示文摘 | Gaizauskas R Demetriou G Artymiuk P J | 2003 | Bioinformatics2003，19，1： | 1 |
| 6 | Efficacy and safetyof regorafenib for advanced gastrointestinal stromal tumours af-ter failure of imatinib and sunitinib (GRID): an international,multicentre, randomised, placebo-controlled, phase 3 trial 显示文摘 | Demetri GD Reichardt P Kang YK | 2013 | Lancet2013，381，9863： | 1 |
| 7 | Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial显示文摘 | Demetri G D Reichardt P Kang Y K | 2013 | Lancet2013，381，9863： | 1 |
| 8 | Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial 显示文摘 | Demetri GD Reichardt P Kang YK | 2013 | Lancet2013，381，： | 1 |
| 9 | Efficacy and safetyof regorafenib for advanced gastrointestinal stromal tumours af-ter failure of imatinib and sunitinib (GRID): an international,multicentre, randomised, placebo-controlled, phase 3 trial 显示文摘 | Demetri GD Reichardt P Kang YK | 2013 | Lancet2013，381，9863： | 1 |
| 10 | Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinih and sunitinib (GRID): an international, multicentre, randomised, placebo -controlled, phase 3 trial显示文摘 | Demetri GD Reichardt P Kang YK | 2013 | Lancet2013，381，9863： | 1 |
| 11 | Using Internal Marketing to Ignite the Corporate Brand:The Case of the UK Retail Bank Industry显示文摘 | IOANNA P DEMETRIS V | 2006 | Journal of Brand Management2006，14，12： | 1 |
| 12 | Efficacy and safety ofregorafenib for advanced gastrointestinal stmmal tumours after failure ofimatinib and sunitinib(GRID):an international,muhieentre,randomised,placebo-controlled,phase 3 trial显示文摘 | Demetri GD Reichardt P Yoon-Koo Kang et a1 | 2013 | Lancet2013，381，9863： | 1 |
| 13 | Complete longitudinalanalyses of the randomized, placebo-controlled, phase Ill trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure显示文摘 | Demetri GD Garrett CR Schoffski P | 2012 | Clin Cancer Res2012，18，11： | 1 |
| 14 | Receptor-binding cancer anti- gen expressed on SiSo cells (RCAS1) expression in human benign and malignant thyroid lesions显示文摘 | Giaginis C Demetriou N Alexandrou P | 2012 | Med Sci Monit2012，18，4： | 1 |
| 15 | Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors 显示文摘 | Demetri GD Lo Russo P MacPherson IR | 2009 | Clin Cancer Res2009，15，： | 1 |
| 16 | Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart,and pancreas islet transplantation 显示文摘 | Rao AS Demetris A J | 1994 | Lancet1994，344，8916： | 1 |
| 17 | Developing optofluidic technology through the fusion of microfluidics and optics显示文摘 | DEMETRI P STEPHEN R Q YANG Chang-hei | 2006 | Nature2006，442，27： | 1 |
| 18 | Electric propulsion and controller design for drag-free spacecraft op- eration显示文摘 | Marchetti P Blandino J J and Demetriou M A | 2008 | Journal of Spacecraft and Rockets2008，45，6： | 1 |
| 19 | Banff schema for grading liver allograft rejection:an international consensus document显示文摘 | Anthony J Demetris Kenneth P | 1997 | Hepatology1997，25，3： | 1 |
| 20 | Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year follow-up显示文摘 | R Kashyap A Jain J Reyes A.J Demetris K.A Elmagd S.F Dodson W Marsh V Madariaga G Mazariegos D Geller C.A Bonham T Cacciarelli P Fontes T.E Starzl J.J Fung | 2001 | Transplantation Proceedings2001，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员